证券代码：688068 证券简称：热景生物 公告编号：2023-029 北京热景生物技术股份有限公司关于 召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 北京热景生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告和 2023 年度第一季度报告，为便于广大投资者更全面 深入地了解公司 2022 年度和 2023 年一季度经营成果、财务状况，公司计划于 2023 年 06 月 02 日下午 13:00-14:00 举行 2022 年度暨 2023 年第一季度业绩说 明会，就投资者关心的问题进行交流。 一、 说明会类型 会议召开时间：2023 年 06 月 02 日(星期五) 下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投 ...

Financial Performance - The net profit attributable to shareholders for 2022 was ¥944,736,633.48, with undistributed profits of ¥2,728,180,599.39 on the parent company’s balance sheet [6]. - The company plans to not distribute cash dividends, issue bonus shares, or convert reserves into share capital for the 2022 profit distribution, opting to carry forward undistributed profits to the next year [6]. - The company's operating revenue for 2022 was approximately ¥3.56 billion, a decrease of 33.76% compared to ¥5.37 billion in 2021 [21]. - The net profit attributable to shareholders for 2022 was approximately ¥944.74 million, down 56.78% from ¥2.19 billion in 2021 [21]. - Cash flow from operating activities for 2022 was approximately ¥978.75 million, a decline of 62.99% from ¥2.64 billion in 2021 [21]. - Basic earnings per share decreased by 56.51% to CNY 10.33 in 2022 from CNY 23.75 in 2021 [22]. - The weighted average return on equity dropped to 30.41% in 2022, down 92.02 percentage points from 122.43% in 2021 [22]. - The gross profit margin for the year was 53.71%, down 5.83 percentage points from the previous year, attributed to declining sales prices of COVID-19 antigen test products [151]. - The company achieved operating revenue of 3,556.55 million RMB, a year-on-year decrease of 33.76% [146]. - The net profit attributable to the parent company was 944.74 million RMB, down 56.78% year-on-year [146]. Risk Factors - There are no significant risk factors that could adversely affect the company during the reporting period [4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [8]. - The company has faced risks related to new product development, including potential delays and failures due to technical route deviations and market positioning issues [136]. - The company is at risk of losing core technical personnel, which could delay ongoing projects and negatively impact future product development [137]. - The company faces risks related to new product registration failures due to regulatory changes and quality management system compliance [138]. - There is a risk of intensified competition in the in vitro diagnostics industry, with potential impacts on market share and profitability [139]. - The pricing model for diagnostic reagents is influenced by government policies, which may lead to price reductions if not managed properly [140]. - The company must continuously upgrade its technology and products to meet market demands, or face risks related to technological obsolescence [143]. - The company is subject to strict regulatory management in the in vitro diagnostics sector, which requires timely adjustments to operational strategies [144]. - The rapid growth of the company necessitates improvements in management and internal controls to maintain competitive advantage [145]. Corporate Governance - The company received a standard unqualified audit report from Rongcheng Accounting Firm [5]. - The board of directors and supervisory board members confirmed the authenticity, accuracy, and completeness of the annual report [4]. - There are no special arrangements for corporate governance applicable to the company [9]. - The company has continuously improved its internal governance and control systems to ensure timely and accurate information disclosure to investors [50]. - The company adheres to strict corporate governance practices, ensuring compliance with relevant laws and regulations [189]. Research and Development - The company is focused on developing new technologies such as Anti-Stokes luminescence and chemiluminescence immunoassay methods [13]. - The company invested a total of 191.14 million yuan in R&D in 2022, a significant increase of 59.22 million yuan, representing a year-on-year growth of 44.89% [38]. - Research and development expenses accounted for 5.37% of operating revenue, an increase of 2.91 percentage points compared to 2.46% in 2021 [22]. - The company has developed a proprietary glycan exosome detection technology, which has received two national invention patents and is aimed at early cancer diagnosis and screening [32]. - The company is advancing its DNA methylation technology for cancer screening, focusing on liver cancer and other gastrointestinal tumors, with a new product "Xiao Wei An" developed for early detection [33]. - The company has registered 19 testing reagent numbers for liver disease diagnosis, including three for liver cancer, and has launched a digital AI diagnostic model for liver cancer risk [35]. - The company has developed a liver cancer early diagnosis reagent kit based on its proprietary technology, which is now commercially available [102]. - The company has established a Future Technology Research Institute to explore cutting-edge technologies in biopharmaceuticals, including antibody drugs, live bacteria drugs, and nucleic acid drugs [185]. - The company has a strong R&D team and has maintained high R&D investment to ensure continuous innovation and technological accumulation [87]. Market Expansion and Strategy - The company aims to enhance its product offerings and market strategies in the upcoming fiscal year [21]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth [29]. - The company is expanding its foreign trade business, but risks from US-China trade tensions and the Russia-Ukraine conflict could impact operations [141]. - The company plans to enhance its market share in clinical medical testing, early liver cancer detection, and public safety testing, with a focus on product innovation and differentiation strategies [184]. - The company is actively exploring innovative biopharmaceuticals, with 8 therapeutic monoclonal antibody projects in development, 4 of which have completed molecular discovery [112]. - The company is strategically expanding into therapeutic antibody drug development and nucleic acid drug research, indicating a diversification of its product offerings [78]. - The company is focused on talent development, implementing training programs and recruitment strategies to attract high-quality talent for various operational areas [187]. - The company is committed to optimizing its production layout and improving operational efficiency through the new production facilities [187]. Product Development and Innovation - The company has developed a unique alpha-fetoprotein heterogeneity test reagent for early liver cancer diagnosis, which is the first of its kind approved by NMPA in China [74]. - The company has developed the "GlyExo-Capture" technology for capturing tumor-specific glycan exosomes, which allows for complete and biologically active exosome separation in just 11 minutes, significantly enhancing early cancer screening capabilities [89]. - The company has launched a home-use COVID-19 antigen self-test kit, which received Emergency Use Authorization (EUA) from the FDA in November 2022, making it one of the few products with multiple international certifications [40]. - The company has developed a portable rapid nucleic acid testing system, integrating multiple advanced technologies for quick detection of respiratory pathogens [41]. - The company has developed a unique immunodiagnostic instrument platform that covers a wide range of applications, making it one of the few suppliers with a comprehensive product line in the industry [124]. Awards and Recognition - As of the end of the reporting period, the company has received over 50 honors, including "Beijing Enterprise Technology Center" and "Beijing Intellectual Property Operation Pilot Unit" [52]. - The company was recognized as a "Little Giant" enterprise in Beijing for 2021 and received multiple awards for its contributions to technology and innovation throughout 2022 [53]. - The company has received multiple awards for its innovative diagnostic technologies, including the National Technology Invention Award and various provincial and national recognitions for its automatic immunoassay analyzers [72][73]. Social Responsibility - The company has actively participated in social responsibility initiatives, donating over RMB 1 million to support pandemic control efforts in various regions [55].

Financial Performance - The company's operating revenue for Q1 2023 was ¥202,939,171.05, representing a decrease of 85.13% compared to the same period last year[5] - The net profit attributable to shareholders was ¥58,884,119.48, down 90.28% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥50,048,505.39, a decline of 91.68% compared to the previous year[5] - The net cash flow from operating activities was -¥242,784,347.60, reflecting a decrease of 506.75% year-over-year[5] - Basic and diluted earnings per share were both ¥0.66, down 89.97% from the previous year[6] - Total operating revenue for Q1 2023 was ¥202,939,171.05, a significant decrease of 85.2% compared to ¥1,364,354,033.74 in Q1 2022[20] - Net profit for Q1 2023 was ¥56,095,829.44, a decline of 90.9% compared to ¥615,406,620.35 in Q1 2022[21] - Basic and diluted earnings per share for Q1 2023 were both ¥0.66, down from ¥6.58 in Q1 2022[22] - The company reported a profit before tax of ¥69,257,895.56 for Q1 2023, down 90.5% from ¥730,908,929.23 in Q1 2022[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,703,810,950.64, a decrease of 5.01% from the end of the previous year[6] - Current assets totaled RMB 1,354,547,109.62, down from RMB 1,798,268,654.72, indicating a decrease of about 24.66%[18] - Cash and cash equivalents were reported at RMB 319,262,764.49, significantly lower than RMB 523,493,118.90 at the end of 2022, representing a decline of approximately 39.0%[17] - The company's accounts receivable increased to RMB 102,912,830.96 from RMB 95,801,252.50, marking an increase of about 7.3%[17] - Non-current assets rose to RMB 2,349,263,841.02 from RMB 2,101,003,185.10, reflecting an increase of approximately 11.8%[18] - The total liabilities decreased to RMB 1,200,000,000.00, down from RMB 1,300,000,000.00, indicating a reduction of about 7.69%[18] - Total liabilities as of Q1 2023 amounted to ¥300,508,546.72, down from ¥545,589,123.77 in the previous year[20] - The company reported a significant reduction in accounts payable, which decreased to RMB 156,534,160.80 from RMB 263,443,202.57, a decline of approximately 40.6%[18] Research and Development - The R&D investment totaled ¥33,864,932.96, a decrease of 26.36% compared to the previous year, while the R&D investment as a percentage of operating revenue increased by 13.32 percentage points to 16.69%[6] - Research and development expenses for Q1 2023 were ¥33,864,932.96, a decrease of 26.4% compared to ¥45,989,803.16 in Q1 2022[21] Market and Business Strategy - The company attributed the significant decline in revenue and profit to the reduced demand for COVID-19 antigen test kits as the pandemic situation improved[10] - The company is focusing on promoting routine clinical testing products, which have surpassed pre-pandemic levels and are experiencing rapid growth[10] - The company is focusing on expanding its market presence and developing new technologies, although specific figures were not disclosed in the report[16] Cash Flow and Investments - Cash inflow from operating activities in Q1 2023 was ¥163,459,229.15, a decrease of 84.8% from ¥1,075,385,948.77 in Q1 2022[24] - The net cash flow from operating activities was -$242.78 million, compared to $59.69 million in the previous year, indicating a significant decline in operational cash generation[25] - Total cash outflow from operating activities amounted to $406.24 million, down from $1.02 billion year-over-year[25] - Cash inflow from investment activities was $607.83 million, while cash outflow was $561.51 million, resulting in a net cash flow from investment activities of $46.32 million, a recovery from a negative $568.74 million last year[25] - The company reported a net decrease in cash and cash equivalents of $204.23 million, compared to a decrease of $509.60 million in the same period last year[26] - The ending balance of cash and cash equivalents was $318.98 million, down from $644.71 million year-over-year[26] - The company received $590.84 million in cash from investment recoveries, a decrease from $757.10 million in the previous year[25] - The cash paid for the acquisition of fixed assets and intangible assets was $126.98 million, compared to $82.74 million last year[25] Accounting and Reporting Changes - The company has implemented new accounting standards starting in 2023, which may affect financial reporting[26] - The report indicates that there are no significant changes in the company's financing or transfer business activities during the reporting period[15]

北京热景生物技术股份有限公司 投资者关系活动记录表 证券简称：热景生物 证券代码：688068 编号：2022-004 | --- | --- | --- | |---------------------|------------------------------------------|--------------------------------------------------------------------| | 投资者关系 活动类别 | 特定对象调研 \n□业绩说明会 □现场参观 | □分析师会议 □媒体采访 \n□新闻发布会 □路演活动 其他（电话会议） | | | 光大证券 | 林小伟 / 黎一江 / 杨硕 / 邓薇 / 印玮洁 杨祎琳 / 章依若 | | | 东吴基金 | 吴佳歆 | | | 弘靖资本 | 高燕 | | | 西部证券 | 王国林 | | | 喜世润投资 | 张北亚 | | | 多鑫投资 | 彭心悦 | | | 人保养老 | 徐文 | | | 嘉实基金 | 孙晓晖 | | | 太平养老 | 姚宏福 | | | | | | 参与单位名 | 上海睿亿投资 | 吕乐艺 | | ...

北京热景生物技术股份有限公司 投资者关系活动记录表 证券简称：热景生物 证券代码：688068 编号：2022-003 | --- | --- | --- | --- | |------------------------------|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

北京热景生物技术股份有限公司 投资者关系活动记录表 证券简称：热景生物 证券代码：688068 编号：2022-005 | --- | --- | --- | |---------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | 特定对象调研 \n□业绩说明会 □现场参观 | □分析师会议 □媒体采访 \n□新闻发布会 □路演活动 其他（电话会议） | | | 袁维 | 国金证券 | | | 王光华 | 银杏全球 | | | 邬安沙 | 源乘投资 | | | 周领 | 慧琛资产 | | | 许征 | 易方达基金 | | | 李勇 | 永安国富 | | | 郝胜涛 | 金鹰基金 | | | 刘恋 | 久铭投资 | | | 魏志华 | 睿郡兴聚 | | | | ...

Financial Performance - The company's operating revenue for Q3 2022 reached ¥963,492,898.68, representing a year-on-year increase of 391.95%[5] - The net profit attributable to shareholders for Q3 2022 was ¥286,732,319.22, an increase of 1,108.80% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥279,157,578.66, up 1,362.08% year-on-year[5] - Year-to-date revenue as of Q3 2022 was ¥3,009,179,202.30, showing a decrease of 20.72% compared to the same period last year[5] - Year-to-date net profit attributable to shareholders was ¥1,101,511,599.04, down 25.39% year-on-year[5] - Basic earnings per share for the current reporting period is 1,108.80 yuan, attributed to an increase in net profit attributable to shareholders[12] - The net profit attributable to the parent company for Q3 2022 was approximately ¥1.10 billion, a decrease of 25.4% compared to ¥1.48 billion in Q3 2021[25] - The basic and diluted earnings per share for Q3 2022 were both ¥11.97, down from ¥16.04 in the same period last year[26] - The total comprehensive income for Q3 2022 was approximately ¥1.11 billion, compared to ¥1.48 billion in Q3 2021, reflecting a decrease of 25.5%[25] Research and Development - The company's R&D investment totaled ¥56,489,528.50 in Q3 2022, an increase of 152.78% compared to the same period last year[6] - The R&D investment as a percentage of operating revenue was 5.86%, a decrease of 5.55 percentage points year-on-year[6] - Total R&D investment for the current reporting period is 152.78 million, mainly due to increases in patent and registration fees, as well as employee compensation[12] - Research and development expenses for the first three quarters of 2022 were CNY 138,276,090.40, up from CNY 82,749,843.72 in 2021, indicating a growth of 67.3%[24] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥3,928,415,132.55, reflecting a growth of 7.78% from the end of the previous year[6] - Total assets increased to CNY 3,928,415,132.55 as of September 30, 2022, compared to CNY 3,644,844,550.64 at the end of 2021, marking an increase of 7.8%[21] - Total liabilities decreased significantly to CNY 348,124,598.11 from CNY 771,014,749.09, a reduction of 54.8%[21] - Shareholders' equity attributable to the company's shareholders increased by 24.48% at the end of the reporting period compared to the end of the previous year, due to an increase in net profit[12] Cash Flow - The company reported a net cash flow from operating activities of ¥708,980,431.99 year-to-date, down 47.55% compared to the previous year[6] - The net cash flow from operating activities for the year-to-date period is -47.55 million, primarily due to a decrease in cash received from sales and services[12] - Cash flow from operating activities for the first nine months of 2022 was ¥2.80 billion, a decline of 27.1% from ¥3.84 billion in the first nine months of 2021[27] - The net cash flow from operating activities for Q3 2022 was ¥708.98 million, down 47.5% from ¥1.35 billion in Q3 2021[28] - The net cash flow from investing activities for the first nine months of 2022 was -¥860.66 million, an improvement from -¥1.32 billion in the same period last year[28] - The company received cash from investment activities totaling ¥2.26 billion in the first nine months of 2022, compared to ¥2.46 billion in the same period of 2021[28] - The company reported a cash outflow from financing activities of ¥417.50 million in the first nine months of 2022, compared to ¥101.70 million in the same period last year[28] Current and Non-Current Assets - The company’s total current assets decreased to CNY 2,216,954,153.41 from CNY 2,517,680,486.33, a decline of 11.9%[19] - The company’s total non-current assets increased to CNY 1,711,460,979.14 as of September 30, 2022, compared to CNY 1,127,164,064.31 at the end of 2021, reflecting an increase of 51.7%[20] - Cash and cash equivalents decreased to CNY 627,247,709.25 as of September 30, 2022, from CNY 1,161,059,870.24 at the end of 2021, representing a decline of 46.0%[19] - Cash and cash equivalents at the end of Q3 2022 were ¥596.78 million, a decrease from ¥316.75 million at the end of Q3 2021[28] Investment Activities - The company reported a significant increase in long-term equity investments to CNY 173,651,875.25 as of September 30, 2022, compared to CNY 151,599,554.36 at the end of 2021, an increase of 14.6%[19] - The company did not report any net profit from subsidiaries prior to consolidation in the current or previous periods[26]

Financial Performance - The company reported a significant increase in revenue during the first half of 2022, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[13]. - The company's operating revenue for the first half of 2022 was ¥2,045,686,303.62, a decrease of 43.17% compared to the same period last year[20]. - The net profit attributable to shareholders was ¥814,779,279.82, down 43.91% year-on-year[21]. - The net cash flow from operating activities decreased by 71.30%, amounting to ¥454,028,287.71[21]. - The company's total assets increased by 5.79% to ¥3,855,706,546.49 compared to the end of the previous year[21]. - Basic earnings per share fell by 43.92% to ¥8.85, while diluted earnings per share also decreased by the same percentage[22]. - The company's revenue for the first half of 2022 reached 204,568.63 million, a decrease of 43.17% compared to the same period in 2021[94]. - The revenue from non-COVID antigen business increased by 39.83% year-on-year, totaling 18,129.67 million[94]. - The magnetic microparticle chemiluminescence method generated revenue of 9,762.31 million, reflecting a growth of 70.35%[94]. Research and Development - The company plans to invest RMB 50 million in R&D for new technologies in the next fiscal year, focusing on molecular diagnostics and liquid biopsy[13]. - The research and development expenditure accounted for 4.00% of operating revenue, an increase of 2.32 percentage points year-on-year[22]. - The company reported a year-on-year increase of 35.40% in R&D expenses, amounting to an increase of ¥21,384,400[23]. - R&D investment reached approximately CNY 81.79 million, a year-on-year increase of 35.40%, representing 4.00% of operating revenue, up from 1.68%[60]. - The company expanded its R&D team to 269 members, a significant increase of 68.13% compared to the same period last year[62]. - The company is actively developing new diagnostic technologies, including liquid biopsy techniques for early cancer screening, based on proprietary technologies such as glycan capture and DNA methylation[71]. Product Development and Innovation - New product development includes the launch of three innovative diagnostic kits, which are expected to contribute an additional RMB 100 million in revenue by the end of 2022[13]. - The company has established eight major clinical diagnostic technology platforms, including magnetic microparticle chemiluminescence and molecular diagnostic technology platforms[30]. - The company’s core products have gained significant market recognition, with a wide range of tests covering various diseases, including liver cancer early diagnosis products being widely used in major hospitals[31]. - The company has developed a unique "GlyExo-Capture" technology for exosome-based early diagnosis of liver cancer, which has received two national invention patents and is expected to be the first exosome liver cancer early diagnosis product approved for market[79]. - The company has launched 8 therapeutic monoclonal antibody projects based on phage display technology, with 4 projects completing molecular discovery and 2 nearing molecular confirmation[54]. Market Expansion and Strategy - The company is actively pursuing market expansion, targeting a 30% increase in market share in the Asia-Pacific region by the end of 2023[13]. - The company is strategically positioned in the in vitro diagnostic market, focusing on immunodiagnosis, POCT, and molecular diagnosis, while also exploring therapeutic antibody drug development[42]. - The company aims to achieve a full-scenario application of immunodiagnostics, from grassroots medical markets to high-end medical markets[31]. - The company is enhancing its international product development efforts to support market expansion in major economies such as the EU, UK, and the US[62]. Awards and Recognition - The company has received multiple awards for its innovative detection methods, including the National Technology Invention Award from the State Council of the People's Republic of China[37]. - The company has been recognized as a leading supplier in the in vitro diagnostic field, particularly in early diagnosis of hepatitis and liver cancer, and has gained significant brand recognition in the COVID-19 testing sector[40]. - The company has received multiple honors, including being recognized as a "Beijing Enterprise Technology Center" and a "National Worker Pioneer" for its COVID-19 testing team[118]. Risks and Challenges - The company has identified potential risks, but none are expected to have a substantial negative impact on operations during the reporting period[4]. - The company faces significant risks in new product development due to the complex and rapidly evolving nature of the in vitro diagnostics industry[122]. - There is a risk of core technical personnel turnover, which could delay ongoing projects and impact future product development[123]. - Increased competition in the in vitro diagnostics market may threaten the company's market share and profitability if it cannot maintain its competitive advantages[128]. Corporate Governance and Compliance - The board of directors confirmed that there are no significant governance issues affecting the integrity of the financial report[5]. - The company has committed to avoid related party transactions and will ensure that any unavoidable transactions are conducted on a fair and reasonable basis[180]. - The company has established a commitment to adhere to legal and regulatory requirements regarding share transfers and disclosures[169]. Social Responsibility and Community Engagement - The company actively fulfills social responsibilities by donating to areas severely affected by the pandemic and participating in rural revitalization efforts[119]. - The company donated RMB 1 million to support COVID-19 prevention efforts in Shaanxi Province and provided medical supplies to various regions[120]. - The company provided 100,000 rapid antigen test kits to the Hong Kong government to assist in combating the pandemic[162].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,364,354,033.74, representing an increase of 11.14% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 605,961,546.65, showing a slight increase of 0.77% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 601,801,232.98, with a year-on-year increase of 0.34%[5]. - Net profit for Q1 2022 reached CNY 615,406,620.35, a slight increase from CNY 601,438,086.05 in Q1 2021, representing a growth of 2.1%[23]. - Basic earnings per share for Q1 2022 were CNY 9.74, compared to CNY 9.67 in Q1 2021, indicating a growth of 0.72%[24]. Cash Flow - The net cash flow from operating activities decreased significantly by 94.21%, amounting to CNY 59,688,999.50[5]. - Cash received from sales of goods and services in Q1 2022 was CNY 1,053,296,630.55, down from CNY 1,642,402,332.61 in Q1 2021, a decrease of 35.8%[25]. - The net cash flow from operating activities was ¥59,688,999.50, a significant decrease from ¥1,030,672,959.16 in the previous year[26]. - Total cash inflow from operating activities amounted to ¥1,075,385,948.77, compared to ¥1,654,548,058.28 in the same period last year[26]. - Cash outflow from operating activities totaled ¥1,015,696,949.27, up from ¥623,875,099.12 year-over-year[26]. - The net cash flow from investing activities was -¥568,742,489.11, slightly improved from -¥587,802,887.57 in the previous year[27]. - Cash inflow from investment activities was ¥764,251,057.89, compared to ¥289,205,000.05 in the same period last year[26]. - Cash outflow from investment activities reached ¥1,332,993,547.00, an increase from ¥877,007,887.62 year-over-year[26]. - The net cash flow from financing activities was not reported, indicating no significant changes in financing during the quarter[27]. - The cash and cash equivalents at the end of the period were ¥644,706,803.08, down from ¥825,519,086.32 at the end of the previous year[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,921,780,780.66, reflecting a growth of 7.60% from the end of the previous year[6]. - The company's total assets reached CNY 3,921,780,780.66 in Q1 2022, up from CNY 3,644,844,550.64 in Q1 2021, representing an increase of 7.6%[20]. - The total liabilities decreased to CNY 431,682,883.24 in Q1 2022 from CNY 771,014,749.09 in Q1 2021, a reduction of 44%[20]. - The total equity attributable to shareholders increased to CNY 3,450,350,484.44 in Q1 2022 from CNY 2,843,524,711.02 in Q1 2021, reflecting a growth of 21.3%[20]. - The company's cash and cash equivalents decreased to RMB 651.46 million from RMB 1.16 billion year-over-year[18]. - The company's trading financial assets increased to RMB 1.05 billion from RMB 927.45 million year-over-year[18]. - Accounts receivable increased by 207.30%, attributed to the expansion of the company's sales scale[10]. - Accounts receivable rose significantly to RMB 114.06 million from RMB 37.12 million year-over-year[18]. - Inventory increased to RMB 346.52 million from RMB 258.62 million year-over-year[18]. - The company's non-current assets totaled RMB 1.58 billion, up from RMB 1.13 billion year-over-year[18]. - The company reported a total of 2.34 billion in current assets, down from 2.52 billion year-over-year[18]. Research and Development - Research and development expenses totaled CNY 45,989,803.16, an increase of 160.95% year-on-year, accounting for 3.37% of operating revenue[6]. - Research and development expenses in Q1 2022 were CNY 45,989,803.16, significantly higher than CNY 17,624,052.30 in Q1 2021, marking an increase of 160.5%[22]. Subsidiaries and Market Expansion - The company established a wholly-owned subsidiary, Hotgen Health Inc., in Albany, New York, with a registered capital of $5 million to develop and sell in vitro diagnostic products, aiming to expand its overseas market presence[15]. - The company set up another wholly-owned subsidiary, Beijing Yujing Pharmaceutical Co., Ltd., with a registered capital of RMB 50 million, focusing on the research of live bacteria drugs and their applications in treating various metabolic and immune diseases[15]. Other Notable Information - The company has not disclosed any significant new product launches or technological advancements during this reporting period[15]. - The company reported a significant increase in investment income by 366.88%, primarily due to higher returns from financial products[10]. - The company received tax refunds amounting to ¥13,825,673.96, compared to ¥1,740,366.34 in the previous year[26]. - The company reported a significant increase in cash received from investment recoveries, totaling ¥757,095,040.00, compared to ¥288,000,000.00 in the same period last year[26].

Financial Performance - The company's operating revenue for 2021 reached ¥5,369,203,761.63, representing a 945.54% increase compared to ¥513,533,629.70 in 2020[19]. - Net profit attributable to shareholders was ¥2,185,763,390.61 in 2021, a significant increase of 1,850.41% from ¥112,066,635.67 in 2020[19]. - The net cash flow from operating activities was ¥2,644,481,598.61, up 1,506.38% from ¥164,624,080.41 in the previous year[19]. - The total assets at the end of 2021 amounted to ¥3,644,844,550.64, a 303.85% increase from ¥902,515,021.55 at the end of 2020[20]. - The company's net assets attributable to shareholders increased by 282.85% to ¥2,843,524,711.02 from ¥742,728,503.81 in 2020[20]. - Basic earnings per share for 2021 were ¥35.14, a dramatic rise of 1,852.22% compared to ¥1.80 in 2020[21]. - The weighted average return on equity increased to 122.43%, up 106.45 percentage points from 15.98% in 2020[21]. - The gross profit margin for the year was 59.54%, a decrease of 3.47 percentage points compared to the previous year[152]. - Operating costs amounted to CNY 2,172,495,474.13, reflecting a year-on-year increase of 1,043.74%[148]. - The company's cash and cash equivalents at the end of the period amounted to 1,161,059,870.24 RMB, representing 31.85% of total assets, an increase of 203.45% compared to the previous year[171]. Research and Development - The company invested 13,191.64 million in R&D during the year, which is a 177.07% increase year-on-year[33]. - The company has developed multiple advanced technology platforms, including sugar capture technology and magnetic microparticle chemiluminescence technology[83]. - The company has five therapeutic monoclonal antibody projects under development, with four completing molecular discovery and two nearing molecular confirmation[86]. - The company has established a future technology research institute to explore cutting-edge technologies in biopharmaceuticals[112]. - R&D investment as a percentage of operating revenue decreased to 2.46% in 2021 from 9.27% in the previous year, a decline of 6.81 percentage points[100]. - The company’s R&D expenditures are entirely expensed, with no capitalized R&D investments reported for the year[99]. - The number of R&D personnel increased to 237, a growth of 86.61% compared to the previous year, with an average salary of 230,800 yuan, up 43.35% year-on-year[101]. - The company aims to optimize its existing R&D environment by increasing funding and human resources to enhance overall R&D capabilities[192]. Product Development and Innovation - The company launched a portable rapid nucleic acid testing system, integrating multiple technologies for quick detection of respiratory pathogens[34]. - The company developed 12 new COVID-19 testing reagents that received 45 international certifications/registrations, including 10 EU CE certificates[35]. - The company has built eight clinical diagnostic product technology platforms, enhancing its strategic layout in the field of in vitro diagnostics[36]. - The company has introduced the "liver cancer early diagnosis triad detection product," which significantly improves liver cancer detection rates[114]. - The GlyExo-Capture® exosome rapid separation system was launched, allowing for complete and biologically active exosome separation in just 11 minutes[114]. - The company is actively developing liquid biopsy technologies for cancer early screening, focusing on glycan exosomes and DNA methylation[54]. - The company has developed and registered 25 new magnetic microparticle chemiluminescence reagents and 3 instruments during the reporting period[87]. - The company has over 40 products in the registration application phase, highlighting its commitment to expanding its product offerings despite regulatory challenges[132]. Market Position and Strategy - The company is positioned in the high-growth in vitro diagnostic industry, which is characterized by high technical content and significant market potential[62]. - The global in vitro diagnostic market exceeded $111.7 billion in 2021, with an estimated compound annual growth rate of approximately 4.5%[61]. - The company is focused on continuous R&D investment to mitigate risks associated with product registration and market demands[130]. - The company plans to continue expanding its market presence, particularly in overseas markets, leveraging the growth of COVID-19 rapid testing products[156]. - The company has strategically entered the immunodiagnostics, POCT, and molecular diagnostics markets, with plans for therapeutic antibody drug development[72]. - The company will enhance its international marketing efforts, leveraging its established brand from COVID-19 antigen self-test products to enter new markets and enhance product recognition[195]. - The company aims to build a full industry chain from diagnosis to treatment, focusing on innovative diagnostic technologies and exploring new fields such as antibody drugs and exosome drugs[103]. Risks and Challenges - The company faces risks related to R&D failures, particularly in the development of therapeutic antibodies, which have high costs and long timelines[129]. - The company is experiencing increased competition in the in vitro diagnostics industry, with both international and domestic players vying for market share[137]. - The pricing of diagnostic products may decline due to intensified market competition and government regulations, impacting the company's revenue[138]. - The company must adapt to regulatory changes in the medical industry to mitigate operational risks[144]. - There is uncertainty regarding the sustainability of overseas sales revenue from COVID-19 antigen rapid tests due to the unpredictable nature of the pandemic[145]. - The company faces risks related to potential overcapacity and asset impairment due to rapid expansion and market changes[140]. Corporate Governance and Compliance - The company has a standard unqualified audit report from Rongcheng Accounting Firm[5]. - The company has no non-operating fund occupation by controlling shareholders or related parties[7]. - The company has no violations of decision-making procedures for external guarantees[7]. - The company emphasizes that forward-looking statements in the report do not constitute a commitment to investors, highlighting investment risks[6]. - The company has been recognized as a "Beijing Intellectual Property Operation Pilot Unit," highlighting its commitment to innovation and intellectual property management[67].